UK markets open in 4 hours 28 minutes

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
2.4260-0.0940 (-3.73%)
At close: 05:29PM CET
Sign in to post a message.
  • g
    geo
    Allarity Therapeutics develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform.

    Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug.
    By screening patients before treatment, the response rate can be significantly increased.

    The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes.

    DRP® is based on messenger RNA from the patient’s biopsies.

    DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial.

    The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.
  • g
    geo
    News:

    Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),
    beta variant B.1351 (“South African” variant), and gamma variant P.1 (“Brazilian” variant).

    Allarity Therapeutics is planning to submit findings to U.S. National Institutes of Health (NIH)
    for funding opportunities as part of the new Antiviral Program for Pandemics (APP)
  • s
    steffen
    selling of private investors shares in allarity - due to tax-reasons. in pension schemes smooth transfer to us-shares. therefor big turn over in shares.

    but new mutations in covid - new business for allarity. good future prospects.
  • E
    Emil
    Valuation!! I think U.S.A. will wake up soon to this bargain price! Upside 1000% from now🇺🇸🚀

    https://hagberganeborn.se/wp-content/uploads/2021/05/allarity-teaser.pdf
  • g
    geo
    This year around December 21 Allarity will move to USA
  • p
    peter
    Where is Jan 🧐 🤣
  • H
    Henrik
    Jan…..How do you think it goes ...... your statements as well as the share price
  • j
    jan
    Where is the covid study registered ???

    There is nothing on clinicaltrials.gov

    Maybe it is a study they conduct in the company canteen
  • g
    geo
    On August 5, the company announced that its oral PARP inhibitor, stenoparib, had demonstrated additional pre-clinical antiviral activity against new variants of Coronavirus.
  • g
    geo
    On July 5, Allarity Therapeutics received acceptance & review notification from the U.S. FDA for the Company’s pre-market approval application for the DRP® for dovitinib.
  • g
    geo
    On September 23, the company announced it would collaborate with Lonza Group to Manufacture dovitinib, Allarity’s most advanced clinical therapeutic candidate.
  • g
    geo
    On July 25, the Allarity announced that it had entered into an agreement with Lantern Pharma for future clinical development of irofulven.
  • g
    geo
    On November 11 the company’s oral PARP inhibitor, stenoparib, had demonstrated pre-clinical antiviral activity against the delta variant of Coronavirus.
  • s
    steffen
    pure buying opportunity - false alarm. it is according to prior decisions. just following the strategy.
    i am buyer - see - price at 8 - 12 in less than half year.
  • s
    steffen
    false alarm. going to bedivided with 50 and after surge
  • j
    jan
    At least it seems some found out what they invested in - Only Avanza bank is buying this.

    Imagine to work for a fund and tell your manager you have bought this - loooooooooooool.

    3,00 is a nice round number down to fair value

    the only meaningfull colaboration this company have is With Canon who supplies cardgridges for the stock printer
  • j
    jan
    Misunderstand what?

    A history of failures?

    3 years to recruit 8 patients at Dana Farber for the PARP study

    17 years in phase 2 for Liplacis. Dumped before phase 3

    Partnering with Cadilla for Liplacis - no upfront - no milestones

    1 person in phase to for Ixempra (dumped in a study in 2009 for safety)

    No active studies for Stenoparip on clinicaltrials.gov. Just pure fluff PR´s

    4 years to file a NDA for dovitinib (a child could have done it faster)

    Partner deal with Smerud - OFC not a dime in upfront. Inferior drugs rarely get that

    More on the first north observation list for fraud than on it

    A share price drop on 97 percent caused by endless broken promises and dilutions

    The founder did the same with Topotarget - again a diluting disaster

    Hire the VP of Mallinkrodt - a walking disaster. Mallinkrodt is now on pink sheets

    And yet a fun fact. This company use the same powerpoint presentations as they did 7 years back on investor presentations.

    I will partly agree the market misunderstood something since the shareprice is 2.84 over what it should be based on value
  • j
    jan
    @Steffen

    There is no Covid study registrered - look it up at clinicaltrials.gov. What they have conducted is no more than a canteen project.

    When you look at clinicaltrials.gov. Look up the former name Oncology Venture to see the pretty list of failures
  • P
    Peter
    The future is soon here and AllarityTherapeutics Drp will be a significant part in the fight against cancer.